No price history available.
Key financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥m | 112,976 | 107,959 | 110,473 | 118,565 | 122,702 | N/A | N/A | N/A |
| Operating profit | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ¥m | 989 | 1,535 | 1,414 | 1,500 | 1,430 | N/A | N/A | N/A |
| EPS reported | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
OLBA HEALTHCARE HOLDINGS, Inc., founded in 1921 and based in Okayama, Japan, provides an extensive range of healthcare and life science solutions to a diverse clientele across the country. Its customers include medical facilities, academic institutions, corporate research laboratories, individuals, and elderly care providers. The company's operations span several key areas. Its Medical Equipment business acts as a wholesale distributor for a wide array of advanced medical devices. This includes prosthetic and implantable items such as artificial joints, pacemakers, and coronary stents; surgical tools like steel instruments and ultrasonic scalpels; and diagnostic imaging systems such, as MRI and CT scanners. Additionally, they supply essential hospital equipment, including respirators, intraoperative monitors, and surgical lighting. In the realm of life sciences, OLBA HEALTHCARE offers specialized reagents and apparatus for genetic research, cell culture, and protein analysis. They also provide automated analyzers for biochemistry, immunology, and blood diagnostics, along with various testing reagents. Furthermore, the company performs dedicated DNA analysis services. The Supply Processing and Distribution (SPD) business supports clients by managing inventory, information, and procurement functions efficiently. Finally, the Nursing Care Products business focuses on enhancing the well-being of those requiring care. This segment offers rental services for nursing care equipment and sells welfare aids such as portable toilets and bathing solutions. They are also involved in managing a program designed to facilitate comfortable long-term care at home, referred to as "long-term care reform." The company rebranded from Kawanishi Holdings, Inc. to OLBA HEALTHCARE HOLDINGS, Inc. in January 2021.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
OLBA HEALTHCARE HOLDINGS, Inc. (2689.T)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
OLBA HEALTHCARE HOLDINGS, Inc., founded in 1921 and based in Okayama, Japan, provides an extensive range of healthcare and life science solutions to a diverse clientele across the country. Its customers include medical facilities, academic institutions, corporate research laboratories, individuals, and elderly care providers. The company's operations span several key areas. Its Medical Equipment business acts as a wholesale distributor for a wide array of advanced medical devices. This includes prosthetic and implantable items such as artificial joints, pacemakers, and coronary stents; surgical tools like steel instruments and ultrasonic scalpels; and diagnostic imaging systems such, as MRI and CT scanners. Additionally, they supply essential hospital equipment, including respirators, intraoperative monitors, and surgical lighting. In the realm of life sciences, OLBA HEALTHCARE offers specialized reagents and apparatus for genetic research, cell culture, and protein analysis. They also provide automated analyzers for biochemistry, immunology, and blood diagnostics, along with various testing reagents. Furthermore, the company performs dedicated DNA analysis services. The Supply Processing and Distribution (SPD) business supports clients by managing inventory, information, and procurement functions efficiently. Finally, the Nursing Care Products business focuses on enhancing the well-being of those requiring care. This segment offers rental services for nursing care equipment and sells welfare aids such as portable toilets and bathing solutions. They are also involved in managing a program designed to facilitate comfortable long-term care at home, referred to as "long-term care reform." The company rebranded from Kawanishi Holdings, Inc. to OLBA HEALTHCARE HOLDINGS, Inc. in January 2021.